191 related articles for article (PubMed ID: 29749433)
1. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
Fu S; Chen X; Lin HJ; Lin J
Int J Oncol; 2018 Jul; 53(1):349-357. PubMed ID: 29749433
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
3. Multiple anti-tumor effects of Reparixin on thyroid cancer.
Liotti F; De Pizzol M; Allegretti M; Prevete N; Melillo RM
Oncotarget; 2017 May; 8(22):35946-35961. PubMed ID: 28415590
[TBL] [Abstract][Full Text] [Related]
4. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.
Shang FM; Li J
Med Clin (Barc); 2019 Jun; 152(11):425-430. PubMed ID: 30340844
[TBL] [Abstract][Full Text] [Related]
5. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
[TBL] [Abstract][Full Text] [Related]
6. Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.
Fu S; Lin J
Anticancer Res; 2018 Nov; 38(11):6271-6279. PubMed ID: 30396947
[TBL] [Abstract][Full Text] [Related]
7. IL-8/CXCR1/2 signalling promotes tumor cell proliferation, invasion and vascular mimicry in glioblastoma.
Sharma I; Singh A; Siraj F; Saxena S
J Biomed Sci; 2018 Aug; 25(1):62. PubMed ID: 30086759
[TBL] [Abstract][Full Text] [Related]
8. [The Effects and Regulatory Mechanism of Targeting CXC Chemokine Receptor 1/2 Combined with Ara-C on the Malignant Biological Behaviors of U937 Cells of Acute Myeloid Leukemia].
Liu YQ; Shen JZ; Yin Y; Chen YT; Yang H; Tang HW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):364-376. PubMed ID: 37096507
[TBL] [Abstract][Full Text] [Related]
9. Cysteine-rich 61 (CCN1) enhances chemotactic migration, transendothelial cell migration, and intravasation by concomitantly up-regulating chemokine receptor 1 and 2.
Lin BR; Chang CC; Chen LR; Wu MH; Wang MY; Kuo IH; Chu CY; Chang KJ; Lee PH; Chen WJ; Kuo ML; Lin MT
Mol Cancer Res; 2007 Nov; 5(11):1111-23. PubMed ID: 18025257
[TBL] [Abstract][Full Text] [Related]
10. The chemokine receptors CXCR1 and CXCR2 regulate oral cancer cell behaviour.
Khurram SA; Bingle L; McCabe BM; Farthing PM; Whawell SA
J Oral Pathol Med; 2014 Oct; 43(9):667-74. PubMed ID: 24965032
[TBL] [Abstract][Full Text] [Related]
11. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
[TBL] [Abstract][Full Text] [Related]
12. An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer.
Mishra A; Suman KH; Nair N; Majeed J; Tripathi V
Mol Biol Rep; 2021 Sep; 48(9):6551-6561. PubMed ID: 34426905
[TBL] [Abstract][Full Text] [Related]
13. Impaired capillary tube formation induced by elevated secretion of IL8 involves altered signaling via the CXCR1/PI3K/MMP2 pathway.
Levy YA; Ciaraldi TP; Henry RR
Mol Biol Rep; 2021 Jan; 48(1):601-610. PubMed ID: 33411234
[TBL] [Abstract][Full Text] [Related]
14. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.
Kemp DM; Pidich A; Larijani M; Jonas R; Lash E; Sato T; Terai M; De Pizzol M; Allegretti M; Igoucheva O; Alexeev V
Oncotarget; 2017 Feb; 8(9):14428-14442. PubMed ID: 28129639
[TBL] [Abstract][Full Text] [Related]
15. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion.
Singh S; Nannuru KC; Sadanandam A; Varney ML; Singh RK
Br J Cancer; 2009 May; 100(10):1638-46. PubMed ID: 19401689
[TBL] [Abstract][Full Text] [Related]
16. Fine-Tuning of GPCR-Chemokine Interactions. Design and Identification of Chemokine Analogues as Receptor Agonists, Biased Agonists, and Antagonists.
Navarro J
Biochemistry; 2019 Mar; 58(10):1432-1439. PubMed ID: 30726064
[TBL] [Abstract][Full Text] [Related]
17. Association of CXCR1 and 2 expressions with gastric cancer metastasis in ex vivo and tumor cell invasion in vitro.
Li Z; Wang Y; Dong S; Ge C; Xiao Y; Li R; Ma X; Xue Y; Zhang Q; Lv J; Tan Q; Zhu Z; Song X; Tan J
Cytokine; 2014 Sep; 69(1):6-13. PubMed ID: 25022956
[TBL] [Abstract][Full Text] [Related]
18. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
Chapman RW; Minnicozzi M; Celly CS; Phillips JE; Kung TT; Hipkin RW; Fan X; Rindgen D; Deno G; Bond R; Gonsiorek W; Billah MM; Fine JS; Hey JA
J Pharmacol Exp Ther; 2007 Aug; 322(2):486-93. PubMed ID: 17496165
[TBL] [Abstract][Full Text] [Related]
19. CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation.
Singh S; Wu S; Varney M; Singh AP; Singh RK
Microvasc Res; 2011 Nov; 82(3):318-25. PubMed ID: 21749879
[TBL] [Abstract][Full Text] [Related]
20. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
